Live Breaking News & Updates on Drug design

Stay informed with the latest breaking news from Drug design on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Drug design and stay connected to the pulse of your community

Xaira launches with $1B+ for AI drug development

In one of the biggest startups ever, Xaira Therapeutics has launched with more than $1 billion from investors. The financing, according to BioWorld records, is roughly equivalent to Roivant Sciences Inc.’s $1.1 billion raise in August 2017 and Galderma Inc.’s $1 billion private placement in June 2023.

Galderma-inc , Roivant-sciences-inc , Xaira-therapeutics , Roivant-sciences , Ai , Machine-learning , Bioworld-science , Drug-design , Rug-delivery-and-technologies , Artificial-intelligence , Financings

Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor

IND-enabling studies expected to begin mid-2024WALTHAM, Mass. and BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced new preclinical data from the Company’s potent, selective, CNS-penetrant ErbB2 inhibitor program. The data are being presented in a poster session at the American Association for Cancer Research (AACR) 2024 Annual Meeting taki

California , United-states , San-diego , American , Andrew-robbins , Christi-waarich , Cogent-biosciences-inc , Company-erb , Cogent-research-team , American-association-for-cancer-research , Nasdaq , Linkedin

AI-driven research identifies pulmonary fibrosis target and inhibitor

Deep learning algorithms have enabled the discovery of molecular structures of interest in biomedicine to design treatments against aggressive diseases such as idiopathic pulmonary fibrosis (IPF). Scientists at Insilico Medicine Inc. selected a target for IPF using artificial intelligence (AI), then designed an inhibitor to block it, and tested it in vitro, in vivo, and in clinical trials.

Scientists-at-insilico-medicine-inc , Insilico-medicine , Bioworld-science , Respiratory , Insilico-medicine-inc- , Idiopathic-pulmonary-fibrosis , Tnik , Tnik-inhibitors , Artificial-intelligence , Drug-design , Rug-delivery-and-technologies

Global AI In Drug Discovery Research Report 2023-2028: Small Molecule, Big Impact - Insights Into AI's Role In Drug Design And Optimization

Global AI In Drug Discovery Research Report 2023-2028: Small Molecule, Big Impact - Insights Into AI's Role In Drug Design And Optimization
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

Dublin , Ireland , United-states , America , Laura-wood , Google , Xtalpi-inc , Market-development , Bpgbio-inc , Atomwise-inc , Iqvia-inc , Illumina-inc

All of Us: 413,000 genomes across ancestries, ages, socioeconomics

Since its founding by the National Institutes of Health (NIH), the scientists of the All of Us Research Program have set the goal to analyze the largest diversity of the genomic population in the country and end the under-representation of its different groups. The project has expanded the vision of several pathologies, discovered thousands of new genetic variants, redefined the risk genes for common diseases, and stratified them, uncovering eight different forms in the case of type 2 diabetes (T2D). Their results create a pathway for a new age of precision medicine.

National-institutes-of-health , Us-research-program , National-institutes , Bioworld-science , All-of-us , Underrepresented-population , Polygenic-risk-scores , Type-2-diabetes , Precision-medicine , Nih , Drug-design

Immunoglobulin G antibody acts as a metabolic aging factor

Immunoglobulin G (IgG), an antibody that participates in the response to infection, could have a specific role in metabolism. During aging, it accumulates in certain tissues inducing metabolic dysfunction and fibrosis of fat tissue. This effect could be prevented through an intracellular receptor that contributes to the delivery of IgG. A team of researchers from Columbia University and Peking University (PKU) demonstrated that reducing excess IgG improved the metabolic health of aged mice and increased their life expectancy.

Peking , Beijing , China , Columbia-university , Peking-university , Bioworld-science , Igg , Fibrosis , Metabolic-dysfunction , Endocrine-metabolic , Drug-design